Skip Navigation

European Heart Journal 1997 18(Supplement E):14-18; doi:10.1093/eurheartj/18.suppl_E.14
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Reid, J. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Reid, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European Society of Cardiology

From kinetics to dynamics: Are there differences between ACE inhibitors?

J. L. Reid

Gardiner Institute, Department of Medicine and Therapeutics, University of Glasgow Glasgow, Scotland

Correspondence: Dr J. L. Reid, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, Scotland

Angiotensin converting enzyme inhibitors are established treatment for hypertension and heart failure. There are well documented differences between ACE inhibitors both in physicochemical properties and pharmacokinetics. Pharmacodynamic actions are similar for most members of the ACE inhibitor class but there are compounds with additional effects which may reflect protease inhibition or non-enzyme-directed pharmacological properties.

Clinically relevant differences are few and far between, particularly in the treatment of hypertension when the optimal dose and dose intervals are used. In heart failure there may be a role for drugs with additional properties such as neutral endopeptidase inhibition. In addition, ACE inhibitors differ in the profile of blood pressure changes after the first dose. Early haemodynamic changes with a fall in blood pressure in heart failure patients may be disadvantageous in terms of subsequent outcome. Thus the haemodynamic effects of the first dose may be relevant to the choice of ACE inhibitors in heart failure.

Key Words: ACE inhibitors • pharmacokinetics • pharmacodynamics • hypertension • heart failure • hypotension


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. de Lorgeril, P. Salen, P. Defaye, P. Mabo, and F. Paillard
Dietary prevention of sudden cardiac death
Eur. Heart J., February 2, 2002; 23(4): 277 - 285.
[Full Text] [PDF]

Home page
 CirculationHome page
M. de Lorgeril, P. Salen, J.-L. Martin, I. Monjaud, J. Delaye, and N. Mamelle
Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction : Final Report of the Lyon Diet Heart Study
Circulation, February 16, 1999; 99(6): 779 - 785.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. de Lorgeril
Dietary arginine and the prevention of cardiovascular diseases
Cardiovasc Res, March 1, 1998; 37(3): 560 - 563.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.